Analysts Offer Predictions for Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Equities research analysts at William Blair issued their Q4 2025 earnings per share estimates for shares of Upstream Bio in a note issued to investors on Thursday, November 7th. William Blair analyst M. Phipps expects that the company will earn ($0.66) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($5.75) per share.

Several other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $38.00 target price for the company. Piper Sandler assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued an “overweight” rating and a $75.00 target price on the stock. Finally, TD Cowen assumed coverage on Upstream Bio in a research note on Tuesday, November 5th. They set a “buy” rating on the stock.

Upstream Bio Trading Down 3.1 %

Shares of UPB opened at $26.18 on Monday. Upstream Bio has a fifty-two week low of $20.74 and a fifty-two week high of $29.46.

Insider Buying and Selling at Upstream Bio

In other news, Director Erez Chimovits purchased 825,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the acquisition, the director now directly owns 4,554,873 shares in the company, valued at approximately $77,432,841. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of Upstream Bio stock in a transaction on Tuesday, October 15th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the purchase, the insider now directly owns 1,175,000 shares of the company’s stock, valued at approximately $19,975,000. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Erez Chimovits bought 825,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the purchase, the director now owns 4,554,873 shares of the company’s stock, valued at approximately $77,432,841. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.